Research Article
Association of Autoimmune Thyroid Disease with Anti-GAD Antibody ELISA Test Positivity and Risk for Insulin Deficiency in Slowly Progressive Type 1 Diabetes
Table 2
Clinical characteristics of the patients based on GADA-RIA, GADA-ELISA, and AITD.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unless noted otherwise, data are shown as median (interquartile range), or number (%). , group B0 versus group C1; , group B1 versus group C1; , group C0 versus group C1; Absolute value of adjusted residual > 1.96. Insulin secretagogues include sulfonylureas, glinides, DPP-4 inhibitors, and GLP-1 receptor agonists. Others include biguanides, thiazolidines, α-glucosidase inhibitors, and SGLT2 inhibitors. T2D, type 2 diabetes; SPT1D, slowly progressive type 1 diabetes; GADA, anti-glutamic acid decarboxylase antibody; ELISA, enzyme-linked immunosorbent assay; BMI, body mass index; RIA, radioimmunoassay; AITD, autoimmune thyroid disease. |